MACULAR PHOTOCOAGULATION STUDY

黄斑光凝研究的目的是评估疗效。 Ar激光光凝治疗视网膜下裂孔 推测为眼部的老年性黄斑变性患者发生新生血管 组织胞浆菌病和特发性视网膜下新生血管。 今年的目标是进入36名患有这三种疾病之一的患者 疾病，用氩激光光凝术治疗其中一半 新的血管网络并允许另一半患者遵循 病程正常，无需治疗。然后可以进行比较，以便在 治疗组和自然病史组。 我们现在总共有14名患者参与研究。这个总数包括九个 老年性黄斑变性类别的患者，一名患者在 推测为眼组织胞浆菌病类，4名特发性患者 类别。已有7名患者被分配接受氩激光治疗。 光凝和七名患者被分配到不接受治疗。

The objective of the Macular Photocoagulation Study is to evaluate the efficacy of argon laser photocoagulation in the treatment of subretinal neovascularization occurring in senile macular degeneration, presumed ocular histoplasmosis, and idiopathic subretinal neovascularization. The goal for this year has to enter 36 patients with one of these three diseases, treating half of them with argon lser photocoagulation to obliterate the new vessel network and allowing the other half of the patients to follow a normal course without treatment. A comparison could then be made between the treated group and the natural history group. We now have a total of fourteen patients in the study. This total includes nine patients in the senile macular degeneration category, one patient in the presumed ocular histoplasmosis category, and four patients in the idiopathic category. Seven patients have been assigned to treatment with argon laser photocoagulation and seven patients have been assigned to no treatment.